Xuyong Wei
Overview
Explore the profile of Xuyong Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1021
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
71.
Pan B, Yang M, Wei X, Li W, Wang K, Yang M, et al.
Aging (Albany NY)
. 2021 Jul;
13(14):18620-18644.
PMID: 34282055
Background: The heterogeneous tumor microenvironment (TME) contributes to poor prognosis of hepatocellular carcinoma (HCC). However, determining the modulation of TME during HCC progression remains a challenge. Methods: Herein, the stromal...
72.
Xu S, Ling S, Shan Q, Ye Q, Zhan Q, Jiang G, et al.
Adv Sci (Weinh)
. 2021 Mar;
8(5):2003042.
PMID: 33717848
Resistance to sorafenib severely hinders its effectiveness against hepatocellular carcinoma (HCC). Cancer stemness is closely connected with resistance to sorafenib. Methods for reversing the cancer stemness remains one of the...
73.
Fan G, Zhang C, Wei X, Wei R, Qi Z, Chen K, et al.
Free Radic Biol Med
. 2021 Mar;
167:1-11.
PMID: 33705959
Rapamycin is a crucial immunosuppressive regimen for patients that have undergone liver transplantation (LT). However, one of the major side effects of rapamycin include metabolic disorders such as dyslipidemia, and...
74.
Wang K, Lu D, Liu Y, Li W, Zhuang L, Ma Z, et al.
Hepatobiliary Surg Nutr
. 2021 Feb;
10(1):9-19.
PMID: 33575286
Background: Early allograft dysfunction (EAD) is associated with decreased graft and patient survival rates. This study aimed to identify the severity of EAD and develop a predictive model for EAD...
75.
Yang M, Tan W, Yang X, Zhuo J, Lin Z, Cen B, et al.
Cancer Biomark
. 2020 Jul;
29(2):197-206.
PMID: 32623388
Background: Precise recipient selection optimizes the prognosis of liver transplantation (LT) for hepatocellular carcinoma (HCC). Alpha-fetoprotein (AFP) is the most commonly used biomarker for diagnosis and prognosis of HCC in...
76.
Fan G, Wei X, Xu X
Ther Adv Med Oncol
. 2020 Jun;
12:1758835920927602.
PMID: 32518599
Hepatocellular carcinoma (HCC) is one of the most severe diseases worldwide. For the different stages of HCC, there are different clinical treatment strategies, such as surgical therapy for the early...
77.
Lin Z, Lu D, Wei X, Wang J, Xu X
Am J Cancer Res
. 2020 May;
10(4):1085-1102.
PMID: 32368387
Treatment of patients with hepatocellular carcinoma (HCC) remains a serious challenge due to high heterogeneity and limited treatment options. In the past few decades, immune therapy, especially immune checkpoint therapy,...
78.
Lu D, Yang F, Zhuo J, Yang M, Lin Z, Jin P, et al.
Clin Transl Gastroenterol
. 2020 May;
11(5):e00168.
PMID: 32358239
Introduction: Antibody to hepatitis B core antigen (HBcAb) is known to be related with the prognosis for patients with hepatocellular carcinoma (HCC). This study aims to evaluate the prognostic capacity...
79.
Wang K, Wei X, Wei Q, Lu D, Li W, Pan B, et al.
Ann Transl Med
. 2020 Mar;
8(4):94.
PMID: 32175387
Background: Early allograft dysfunction (EAD) following liver transplantation is associated with poor recipient and graft survival. In recent years, circular RNAs (circRNAs) have emerged as important components of endogenous RNAs....
80.
Al-Ameri A, Wei X, Wen X, Wei Q, Guo H, Zheng S, et al.
Transpl Int
. 2020 Jan;
33(7):697-712.
PMID: 31985857
Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is a significant clinical problem associated with poor surgical outcomes. This study aims to summarize the current evidence on risk prediction...